INVO Bioscience, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (Nasdaq: INVO) on August 8, 2023, covering events occurring on August 4, 2023, and August 8, 2023. The filing details the entry into a material definitive agreement for a public equity offering and the subsequent closing of that offering.
Key Financial Metrics and Capital Structure
The Company closed a public offering on August 8, 2023, raising gross proceeds of approximately $4.5 million. The offering consisted of 1,580,000 units sold at $2.85 per unit. Each unit comprised one share of common stock and two warrants exercisable at $2.85 per share.
- Gross Proceeds: Approximately $4.5 million.
- Placement Agent Fees: 7.0% of gross proceeds (5.0% for certain investors) plus warrants to purchase up to 110,600 shares at $3.14 per share.
- Debt Repayment Plan: The Company intends to use net proceeds to repay specific obligations, including a Standard Merchant Advance Agreement (up to $543,750), an 8% Debenture to Peak One Opportunity Fund LP ($100,000 plus accrued interest/fees), and an 8% Debenture to First Fire Global Opportunities Fund, LLC ($39,849 plus accrued interest/fees).
Material Changes and Use of Proceeds
The primary material change is the influx of capital and the reduction of existing debt obligations. The Company outlined a specific allocation for the net proceeds:
- Acquisition Funding: Up to $2,125,000 for the initial installment of the purchase price for the acquisition of the Wisconsin Fertility Institute (net of a $350,000 holdback).
- Contractual Fees: $1,000,000 to pay Armistice an amendment fee for removing the Subsequent Equity Financing Provision from the Armistice SPA.
- Working Capital: Remaining net proceeds will be used for working capital and general corporate purposes.
Guidance, Outlook, and Restrictions
The filing includes significant restrictions on future equity issuances and insider trading:
- Issuance Restrictions: For 90 days post-offering, the Company is restricted from issuing common stock or equivalents, with an exception allowing up to $1,000,000 in issuances after 45 days if the price is $2.85 or higher. Variable Rate Transactions are prohibited for one year.
- Lock-Up Agreements: Officers, directors, and holders of 5% or more of outstanding common stock are subject to a six-month lock-up period, prohibiting the sale or transfer of securities.
- Forward-Looking Statements: The Company cautions that actual results may differ from expectations due to risks, including the ability to maintain Nasdaq listing status.
Investor Verification Checklist
- Verify the final net proceeds after deducting placement agent fees and offering expenses.
- Confirm the status of the acquisition of the Wisconsin Fertility Institute and the $350,000 holdback conditions.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and redemption rights.
- Monitor the Company's compliance with the 90-day and 1-year issuance restrictions to prevent unexpected dilution.
- Check subsequent filings for confirmation of the debt repayments to Cedar Advance, Peak One, and First Fire Global.